Inventor · disambiguated record
David E. Nichols
Also filed as: NICHOLS DAVID · NICHOLS DAVID E · NICHOLS DAVID EARL
31 granted patents·15 pending applications·363 citations·filing 1973–2025
97Inventor score
Files withCOMPASS PATHFINDER LTD23PURDUE RESEARCH FOUNDATION6ELEUSIS THERAPEUTICS US INC5DARPHARMA INC32A BIOSCIENCES INC1
Top patents by PatentIndex Score
46 records- 0198US11939346B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2023·Granted Mar 26, 2024·6 cites·28 claims
- 0298US11629159B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2022·Granted Apr 18, 2023·10 cites·30 claims
- 0398US11180517B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2021·Granted Nov 23, 2021·22 cites·25 claims
- 0498US11149044B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2021·Granted Oct 19, 2021·18 cites·22 claims
- 0598US10954259B1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2020·Granted Mar 23, 2021·22 cites·23 claims
- 0698US10947257B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2020·Granted Mar 16, 2021·23 cites·23 claims
- 0797US11851451B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2022·Granted Dec 26, 2023·5 cites·30 claims
- 0897US11505564B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2019·Granted Nov 22, 2022·13 cites·26 claims
- 0997US11447510B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2021·Granted Sep 20, 2022·13 cites·27 claims
- 1096US10519175B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHWAYS LTD·Filed 2018·Granted Dec 31, 2019·51 cites·21 claims
- 1195US12447164B2Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2023·Granted Oct 21, 2025·3 cites·33 claims
- 1295US11564935B2Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2021·Granted Jan 31, 2023·9 cites·27 claims
- 1394US11865126B2Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2023·Granted Jan 9, 2024·5 cites·30 claims
- 1494US11738035B2Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2022·Granted Aug 29, 2023·6 cites·29 claims
- 1592US12312375B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2024·Granted May 27, 2025·0 cites·30 claims
- 1692US5047536AHexahydrobenzo(A)phenanthridine compoundsPURDUE RESEARCH FOUNDATION·Filed 1989·Granted Sep 10, 1991·39 cites·5 claims
- 1792US4000197AAsymmetric synthesis of phenylisopropylaminesUNIV IOWA RES FOUND·Filed 1973·Granted Dec 28, 1976·29 cites·22 claims
- 1891US11312684B1Pharmaceutically acceptable salts of psilocin and uses thereofELEUSIS THERAPEUTICS US INC·Filed 2021·Granted Apr 26, 2022·31 cites·17 claims
- 1991US2025361251A1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2025·Application pending·0 cites
- 2091US2025368665A1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2025·Application pending·0 cites
- 2190US12433904B2Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2020·Granted Oct 7, 2025·2 cites·32 claims
- 2290US11680043B2Pharmaceutically acceptable salts of psilocin and uses thereofELEUSIS THERAPEUTICS US INC·Filed 2022·Granted Jun 20, 2023·5 cites·16 claims
- 2390US2024199660A1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2024·Application pending·0 cites
- 2489US2025367223A1Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybinCOMPASS PATHFINDER LTD·Filed 2025·Application pending·0 cites
- 2588US2025304607A1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2025·Application pending·0 cites
- 2686US2025302851A1Methods of treating neurocognitive disorders, chronic pain and reducing inflammationCOMPASS PATHFINDER LTD·Filed 2025·Application pending·0 cites
- 2784US12377112B2Methods of treating neurocognitive disorders, chronic pain and reducing inflammationCOMPASS PATHFINDER LTD·Filed 2020·Granted Aug 5, 2025·1 cites·27 claims
- 2879US12459965B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useCOMPASS PATHFINDER LTD·Filed 2024·Granted Nov 4, 2025·0 cites·10 claims
- 2975US6916823B2Method of treatment of dopamine-related dysfunctionUNIV NORTH CAROLINA·Filed 2002·Granted Jul 12, 2005·12 cites·13 claims
- 3068US6413977B1Chromeno[4,3,2-DE]isoquinolines as potent dopamine receptor ligandsPURDUE RESEARCH FOUNDATION·Filed 2000·Granted Jul 2, 2002·5 cites·26 claims
- 3165US6916832B2Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligandsPURDUE RESEARCH FOUNDATION·Filed 2002·Granted Jul 12, 2005·3 cites·12 claims
- 3265US2025353808A15-methoxymethyl and 5-hydroxymethyl phenethylamines2A BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3359US5420134ASubstituted hexahydrobenzo[A]phenanthridinesPURDUE RESEARCH FOUNDATION·Filed 1993·Granted May 30, 1995·15 cites·20 claims
- 3459US2025073207A1Psilocin benzoate formulation for intravenous infusionELEUSIS THERAPEUTICS US INC·Filed 2023·Application pending·0 cites
- 3558US12398093B2Compounds and methods for treating inflammatory disordersUNIV LOUISIANA STATE·Filed 2020·Granted Aug 26, 2025·0 cites·18 claims
- 3654US2010041690A1Co-Administration of Dopamine-Receptor Binding CompoundsDARPHARMA INC·Filed 2009·Application pending·0 cites
- 3752US8318938B2Trans-fused chromenoisoquinolines synthesis and methods for useNICHOLS DAVID·Filed 2008·Granted Nov 27, 2012·0 cites·45 claims
- 3851US2024124398A1Pharmaceutically acceptable salts of psilocin and uses thereofELEUSIS THERAPEUTICS US INC·Filed 2022·Application pending·0 cites
- 3949US6194423B1Fused isoquinolines as dopamine receptor ligandsPURDUE RESEARCH FOUNDATION·Filed 1999·Granted Feb 27, 2001·9 cites·16 claims
- 4048US2007155720A1Co-administration of dopamine-receptor binding compoundsDARPHARMA INC·Filed 2004·Application pending·0 cites
- 4147US2023277568A1Method of treatment for psilocybin or psilocin infusionELEUSIS THERAPEUTICS US INC·Filed 2021·Application pending·0 cites
- 4245US2007254906A1Method of Administration of Dopamine Receptor AgonistsDARPHARMA INC·Filed 2005·Application pending·0 cites
- 4344US5959110AFused isoquinolines as dopamine receptor ligandsPURDUE RESEARCH FOUNDATION·Filed 1996·Granted Sep 28, 1999·6 cites·10 claims
- 4444US2005232870A1Method of treatment of dopamine-related dysfunctionPURDUE RES FOUNDATION AND UNIV·Filed 2005·Application pending·0 cites
- 4543US2020345858A1Compositions and methods for the prevention and treatment of ergot alkaloid toxicityLIGHT LINDA·Filed 2018·Application pending·0 cites
- 4640US9359303B2Octahydrobenzoisoquinoline modulators of dopamine receptors and uses thereforNICHOLS DAVID E·Filed 2010·Granted Jun 7, 2016·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when David E. Nichols files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →